Opto Circuits' subsidiary Eurocor announces Study results of Valentines Trial I

- **DIOR® (DEB) shows effective and safe treatment for cases of In-Stent Restenosis (ISR)**
- **Database with largest group of patients ever enrolled to show effectiveness of DEB in treatment of ISR**

Washington DC, USA | Bonn, Germany | Bengaluru, India
March 3, 2011

Eurocor GmbH, the Bonn-based subsidiary of Opto Circuits (India) Ltd; presented the first eight month follow-up data from the Valentines Trial I Global Registry on March 1st 2011 during the CRT 2011 Meeting. Eurocor's groundbreaking Valentines Trial I was conducted with an objective to assess the efficacy of the paclitaxel-eluting balloon Dior®- II for In-stent Restenosis (ISR) following Bare Metal Stent (BMS) and Drug-eluting Stent (DES) implantation at 6-9 months. 300 patients (those suffering from ISR) were enrolled by 96 Investigators from 26 countries starting 14th February 2010 and the initial eight-month follow-up data was announced Tuesday by principal investigator Prof. Dr. Sigmund Silber of Munich, Germany during the Conference. This landmark clinical study represents the largest group of patients ever enrolled in a study on the effectiveness of DEB in the treatment of ISR.

The Results: The eight-month results very clearly and convincingly showed that the DIOR® DEB is a very effective and safe treatment for cases of in-stent restenosis, both for bare-metal (BMS) and Drug-eluting (DES) devices. The treatment with DIOR® DEB resulted in very low Target Lesion Revascularization (TLR) rates of 7.4% on average, 5.9% for bare-metal stents and 9.8% for Drug-eluting stents. This compares to TLR rates of up to 20% for vascular brachytherapy. The study results further showed DIOR® DEB to be effective in patients that suffer from diabetes with a TLR rate of an average of 11.5%.

"Single digit TLR rates for the treatment of both BMS and DES for in-stent restenosis, this is a very remarkable result, especially taking into consideration the profound disease the patients suffer from." **Prof. Dr. Sigmund Silber** pointed out during the presentation.

"It has been a major challenge to compile this innovative study design. We are thankful and proud that all went well. I am sure the investigators and eurocor have developed a database which will impact treatment and help patients to recover from Cardiovascular disease" **Dr. Rembert Pogge von Strandmann**, Director Clinical & Regulatory; Scientific PR commented.

Management Comments: Vinod Ramnani, Chairman and Managing Director, Opto Circuits (India) Ltd. - the parent company of Eurocor GmbH: "We are extremely pleased with the results of the initial eight month follow-up in this landmark clinical study. DIOR® has performed impressively for a very demanding indication and in a difficult patient group. We are committed to further increase the clinical database of patients treated with our innovative and proprietary Drug-eluting balloon products DIOR® and FREEWAY® and have already commenced enrollment in Valentines Trial II aimed at de-novo lesion indications for DIOR®."

Detailed Trial Results available at: http://www.valentines-trial.com/

About: DIOR®

DIOR® is a patent-pending drug (paclitaxel) -eluting breakthrough balloon dilatation catheter developed by scientists at Eurocor and used by hundreds of interventional cardiologists across the world. It can be effectively used in patients with in-stent restenosis, bifurcation lesions and lesions in small vessels. More information available at: http://www.eurocor.de/products/dior/product_information/